Guggenheim Raises AnaptysBio (NASDAQ:ANAB) Price Target to $90.00

AnaptysBio (NASDAQ:ANAB) had its price target lifted by Guggenheim from $75.00 to $90.00 in a research report released on Monday, Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other equities analysts also recently issued reports on ANAB. JPMorgan Chase & Co. raised their price objective on shares of AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and set a $55.00 price target on shares of AnaptysBio in a research note on Wednesday, August 14th. Wedbush restated an “outperform” rating and issued a $42.00 price objective on shares of AnaptysBio in a research note on Thursday, September 26th. Finally, Truist Financial lifted their target price on AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, AnaptysBio has an average rating of “Moderate Buy” and an average price target of $54.64.

AnaptysBio Trading Down 1.1 %

NASDAQ:ANAB opened at $34.75 on Monday. The company has a 50 day simple moving average of $35.50 and a two-hundred day simple moving average of $29.63. The company has a market cap of $949.34 million, a PE ratio of -5.66 and a beta of -0.29. AnaptysBio has a 12 month low of $13.36 and a 12 month high of $41.31.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). The firm had revenue of $10.97 million for the quarter, compared to analysts’ expectations of $25.85 million. AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. Research analysts forecast that AnaptysBio will post -6.84 earnings per share for the current year.

Insider Transactions at AnaptysBio

In other AnaptysBio news, major shareholder Ecor1 Capital, Llc bought 273,972 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The shares were bought at an average price of $36.50 per share, with a total value of $9,999,978.00. Following the purchase, the insider now owns 7,794,996 shares of the company’s stock, valued at $284,517,354. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other AnaptysBio news, CFO Dennis Mulroy sold 12,220 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the sale, the chief financial officer now owns 4,744 shares in the company, valued at $189,333.04. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Ecor1 Capital, Llc acquired 273,972 shares of the business’s stock in a transaction dated Wednesday, August 14th. The shares were purchased at an average price of $36.50 per share, with a total value of $9,999,978.00. Following the transaction, the insider now owns 7,794,996 shares of the company’s stock, valued at approximately $284,517,354. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 22,440 shares of company stock valued at $892,936 over the last 90 days. Company insiders own 33.70% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANAB. Allspring Global Investments Holdings LLC purchased a new stake in shares of AnaptysBio during the 1st quarter worth approximately $38,000. Values First Advisors Inc. purchased a new stake in AnaptysBio during the third quarter valued at $49,000. nVerses Capital LLC lifted its position in AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 1,400 shares during the last quarter. Headlands Technologies LLC grew its stake in shares of AnaptysBio by 444.8% in the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock worth $89,000 after buying an additional 2,900 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of AnaptysBio in the 1st quarter worth about $222,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.